Biopharmaceutical company Akebia Therapeutics (NASDAQ:AKBA) has received a response for its formal dispute resolution request associated with the complete response letter (CRL) for vadadustat.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
In the written response, the Office of New Drugs (OND) denied AKBA’s appeal but provided the company a path to resubmit the new drug application (NDA) for vadadustat for the treatment of anemia in dialysis-dependent patients.
Importantly, the OND has suggested a Type A meeting between the company and the division and AKBA now plans to request a meeting at the earliest and resubmit the NDA in the second half of this year.
Additionally, vadadustat has already bagged approval in 33 countries with a European launch expected by the end of this year.
With today’s price gains, AKBA shares have now gained nearly 93.5% so far this year.
Read full Disclosure